Dr. Alemany is an internationally recognized expert in oncolytic adenoviruses for cancer treatment. He has more than 80 original publications and numerous patents in the fields of Gene Therapy and Virotherapy. He acts as editor and reviewer for the main international journals in these fields. From 1994 to 2001, Dr. Alemany held various research positions in USA at the MD Anderson Cancer Center (Houston, TX), Baxter Healthcare (Round Lake, IL), and the University of Alabama at Birmingham. He established the Virotherapy Group at the Translational Research Laboratory of the Institut CatalÓ d'Oncologia in 2001 and co-founded VCN together with Drs. Cascallˇ and CapellÓ in 2009 as a spin-off from this group. Dr. Alemany has been on the Executive Board of the Spanish Society of Gene and Cell Therapy and consultant for several companies based on adenoviruses.
Dr CapellÓ is an internationally recognized expert in molecular oncology and hereditary cancer, having published more than 200 original papers and reviews. He has been actively working in the development of new tumor biomarkers, and has collaborated with several biotechnological companies.
He possesses strong directive skills and expertise in team management and has held different responsibilities in research and scientific strategy. Dr. CapellÓ is the Director of the Translational Research Laboratory at Institut CatalÓ d'Oncologia (ICO-IDIBELL) from the year 2002, a position that he currently combines with the Scientific Direction of the Institut de Recerca BiomŔdica de Bellvitge (IDIBELL) .
Dr. Büscher holds a PhD in Biology, from the University of Hannover, Germany, and obtained an International Executive MBA from the Instituto de Empresa, Madrid. He received his PhD in Immunology, and focused his postdoctoral work at the Salk Institute, La Jolla, California, on molecular developmental biology and stem cell research. In 2004 he joined Cellerix SA, a Madrid-based cell therapy company, and from 2007 on occupied the position of Vice President of R&D. He had been in charge of the preclinical and CMC program of Cellerix, and represented the company in several scientific advices at EMA. Dirk Büscher is inventor on several patents related to stem cell technology. He further has served as industry expert on mesenchymal stem cells in internal EMA workshops
In 2010 he accepted a position as chief executive officer of Gri-Cel, a newly created subsidiary of Grifols, Barcelona, dedicated to advanced therapies and innovative therapeutic approaches. He currently serves on two boards of biotech companies, in which Grifols holds a significant participation.
Dr. Terencio holds a Master in R+D of Drugs by the University of Navarra, a PhD in CNS Pharmacology by the University of Barcelona, as well as a Development Management Program (PDD) by IESE Business School. He has more than 17 years of experience in the Biopharmaceutical industry holding several positions. Before joining Grifols, he was in charge of the Biochemistry and Molecular Biology Department in the Drug Discovery Area for Grupo Ferrer. In 2008 he was appointed at Grifols as R+D Director of one of the subsidiaries, Laboratorios Grifols. Two years later, he became the COO at Gri-Cel, a new subsidiary of Grifols aimed to invest in advanced therapies as well as innovative therapeutic approaches.
During his professional career, Dr. Terencio has worked in several therapeutic areas, CNS, Cardiovascular, Oncology and Infectious Diseases. His main scientific expertise is within the field of Drug Discovery and Development of Small Molecules. In the last few years, as COO of Gri-Cel his focus has moved into the assessment and management of projects involving Biotech companies, specifically those related with innovative therapies.
Dr Cascallˇ is an expert in oncolytic therapies and gene therapy, a field in which has been involved from his PhD. Author of many original scientific papers and reviews in peer-reviewed journals, he is co-inventor of 5 patents on the use of adenovirus as antitumoral agents. He has been a researcher at the University of Barcelona (Spain), at the MD. Anderson Cancer Center de Houston (Houston, USA), at Merck Farma y QuÝmica (Barcelona, Spain), and since 2001 at the Virotherapy Group of the Intitut CatalÓ d'Oncologia (ICO) ľ IDIBELL. During his professional career Dr. Cascallˇ has always been focused in the development of new biotechnological agents for cancer treatment where he has lead different multidisciplinary teams. He possesses a solid expertise in Regulatory Affairs in Gene Therapy and has acted as Expert for the European Medicines Agencies (EMA). Additionally Dr. Cascallˇ is Member of the Biosafety Committee at IDIBELL where he is actively involved in the supervision of research protocols and provides advice in biosafety-related issues. Dr. Cascalló has also received formation in the management of Biotechnological Companies by the University of Cambridge (UK), and posseses a solid basis in Executive Management by the internationally recognized IESE Business School.